Log in to search using one of your social media accounts:

 

Vertex Seeks Approval for Experimental Cystic-Fibrosis Drug
Vertex Pharmaceuticals said it would seek regulatory approval for one of its experimental cystic-fibrosis drugs after the treatment helped improve patients ’ lung function in late-stage studies. (Source: WSJ.com: Health)
Source: WSJ.com: Health - March 28, 2017 Category: Pharmaceuticals Tags: PAID Source Type: news

Vertex cystic fibrosis combination succeeds in late-stage trials
(Reuters) - Vertex Pharmaceuticals Inc said on Tuesday its Kalydeco cystic fibrosis treatment given with an experimental drug demonstrated significant improvements in lung function in a pair of late-stage trials the company plans to use to seek approval of the combination therapy. (Source: Reuters: Health)
Source: Reuters: Health - March 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Vitamins could help treat cystic fibrosis, research finds
Researchers have discovered why antibiotics for treating people with cystic fibrosis are becoming less effective and how fat soluble vitamins might offer a viable solution. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 27, 2017 Category: Science Source Type: news

Genetics reveal mysteries of hard-to-treat bacterial infection in cystic fibrosis
New research on bacteria that cause major problems for those with cystic fibrosis reveals clues as to how it proliferates for so long in the lungs and offers new ideas for treatments to explore. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 27, 2017 Category: Science Source Type: news

Potential of stem cell therapy to repair lung damage
A new study has found that stem cell therapy can reduce lung inflammation in an animal model of chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Although, still at a pre-clinical stage, these findings have important potential implications for the future treatment of  patients. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 27, 2017 Category: Science Source Type: news

Genetics reveal mysteries of hard-to-treat bacterial infection in cystic fibrosis
(University of British Columbia) New UBC research on bacteria that cause major problems for those with cystic fibrosis reveals clues as to how it proliferates for so long in the lungs and offers new ideas for treatments to explore. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 27, 2017 Category: Infectious Diseases Source Type: news

Concert rebuffed $250M buyout offer from Vertex before CF drug deal
Lexington-based Concert Pharmaceuticals rebuffed a $250 million buyout offer from Vertex Pharmaceuticals in November before ultimately striking a deal earlier this month to sell a cystic fibrosis drugs to the Boston company for $160 million, according to a federal filing. The filing on Thursday by Concert (Nasdaq: CNCE) offers new details about the negotiations leading up to its March 6 deal with Vertex(Nasdaq: VRTX). Under the agreement, Vertex is slated to acquire the 69-employee biotech’s cystic… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 24, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Study shows potential of stem cell therapy to repair lung damage
(European Lung Foundation) A new study has found that stem cell therapy can reduce lung inflammation in an animal model of chronic obstructive pulmonary disease (COPD) and cystic fibrosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 24, 2017 Category: Global & Universal Source Type: news

New study resolves the structure of the human protein that causes cystic fibrosis
In order to better understand how genetic mutations give rise to cystic fibrosis, researchers need to map the protein responsible for the disorder. The new structure has led to new insights on how this molecular channel functions. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 23, 2017 Category: Science Source Type: news

New study resolves the structure of the human protein that causes cystic fibrosis
In order to better understand how genetic mutations give rise to cystic fibrosis, researchers need to map the protein responsible for the disorder. The new structure has led to new insights on how this molecular channel functions. More » (Source: The Rockefeller University Newswire)
Source: The Rockefeller University Newswire - March 23, 2017 Category: Biomedical Science Authors: Wynne Perry Tags: Science News CFTR cystic fibrosis David C. Gadsby Jue Chen Laboratory of Cardiac and Membrane Physiology Laboratory of Membrane Biology and Biophysics structural and chemical biology Source Type: news

Tackling a Decade of Change
There has never been a more exciting time to be in the pharmaceutical industry – if you like change, that is. While change is a constant in business, pharma has experienced unprecedented levels over the past decade, says Alistair Grenfell, President, North Europe, Middle East and Africa, at QuintilesIMS.“At a time when we are seeing a huge amount of innovation in our science and our pipeline – creating great excitement among the healthcare community – we need to acknowledge that our world has changed,” says Grenfell. “If you wind the clock back to 2005 and look at the top 10 selling medi...
Source: EyeForPharma - March 23, 2017 Category: Pharmaceuticals Authors: Hugh Gosling Source Type: news

New study resolves the structure of the human protein that causes cystic fibrosis
(Rockefeller University) In order to better understand how genetic mutations give rise to cystic fibrosis, researchers need to map the protein responsible for the disorder. The new structure has led to new insights on how this molecular channel functions. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 23, 2017 Category: Biology Source Type: news

Galapagos begins Phase I trial of GLPG0367 to treat cystic fibrosis
Belgium-based biopharmaceutical firm Galapagos has begun the Phase I clinical trial of GLPG3067 for the treatment of patients with cystic fibrosis (CF). (Source: Drug Development Technology)
Source: Drug Development Technology - March 23, 2017 Category: Pharmaceuticals Source Type: news

From Genome Research: Pathogen demonstrates genome flexibility in cystic fibrosis
(Cold Spring Harbor Laboratory) Chronic lung infections can be devastating for patients with cystic fibrosis (CF), and infection by Burkholderia cenocepacia, one of the most common species found in cystic fibrosis patients, is often antibiotic resistant. In a study published today in Genome Research, scientists sequenced and phenotyped multiple B. cenocepacia isolates from 16 CF patients. They found extensive variation among isolates during chronic lung infection as well as changes in clinically relevant bacterial phenotypes. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 21, 2017 Category: Infectious Diseases Source Type: news

PodMed: A Medical News Roundup From Johns Hopkins (with audio)
(MedPage Today) -- This week's topics include managing after DVT, anticoagulation in folks with Afib, surviving with cystic fibrosis, and where to have rehabilitation after knee replacement. (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - March 18, 2017 Category: Pediatrics Source Type: news

Canadians With Cystic Fibrosis Live 10 Years Longer Than Americans With the Disease
Canadians with cystic fibrosis survive on average more than 10 years longer than Americans with the disease. Health insurance differences may be why. (Source: NYT Health)
Source: NYT Health - March 15, 2017 Category: Consumer Health News Authors: NICHOLAS BAKALAR Tags: Cystic Fibrosis Health Insurance and Managed Care Transplants Medicare Source Type: news

Cystic Fibrosis Patients in Canada Live Longer Than Those in U.S.
Canadians with cystic fibrosis live about 10 years longer on average, researchers say (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - March 15, 2017 Category: Respiratory Medicine Tags: Family Medicine, Internal Medicine, Nursing, Pathology, Pediatrics, Pulmonology, Journal, Source Type: news

Cystic Fibrosis Survival Better in Canada Than in U.S.
Canadians with the lung disease live about 10 years longer on average, study finds Source: HealthDay Related MedlinePlus Page: Cystic Fibrosis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 14, 2017 Category: Consumer Health News Source Type: news

Cystic Fibrosis Survival Better in Canada Than in U.S.
Title: Cystic Fibrosis Survival Better in Canada Than in U.S.Category: Health NewsCreated: 3/13/2017 12:00:00 AMLast Editorial Review: 3/14/2017 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - March 14, 2017 Category: Respiratory Medicine Source Type: news

Cystic Fibrosis Survival Better in Canada Than in U.S.
Canadians with the lung disease live about 10 years longer on average, study finds (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - March 14, 2017 Category: Respiratory Medicine Authors: webmaster at doctorslounge.com Tags: Family Medicine, Nursing, Pulmonology, Nutrition, Organ Transplants, News, Source Type: news

Canadians with Cystic Fibrosis Live Roughly 10 Years Longer Than Americans (FREE)
By Kelly Young Edited by Jaye Elizabeth Hefner, MD Canadian patients with cystic fibrosis have a survival advantage over their U.S. counterparts, according to a study in the Annals of Internal Medicine. … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 13, 2017 Category: Primary Care Source Type: news

Cystic fibrosis patients live 10 years longer in Canada
Although the neighboring countries have the same proportion of cystic fibrosis patients, Canadians are far more likely to receive a lung transplant than Americans with the same incurable disease. (Source: the Mail online | Health)
Source: the Mail online | Health - March 13, 2017 Category: Consumer Health News Source Type: news

Canadians With Cystic Fibrosis Outlive US Patients by 10 Years Canadians With Cystic Fibrosis Outlive US Patients by 10 Years
Differences between the health systems in the United States and Canada, including access to transplants, likely explain why Canadian patients with CF live longer than their US counterparts.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 13, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Cystic fibrosis patients live longer in Canada than in U.S.
(Reuters Health) - Canadians with cystic fibrosis, a life threatening inherited disorder of the lungs and digestive system, tend to survive about a decade longer than American patients, a new study suggests. (Source: Reuters: Health)
Source: Reuters: Health - March 13, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

CF patients survive 10 years longer in Canada than in US
Canadians with cystic fibrosis live, on average, 10 years longer than their counterparts in the United States, according to a study published Monday in Annals of Internal Medicine. (Source: CNN.com - Health)
Source: CNN.com - Health - March 13, 2017 Category: Consumer Health News Source Type: news

Why Canadians with cystic fibrosis live 10 years longer than patients in U.S.
Over the last two decades there’s been a big improvement in survival rates for people with cystic fibrosis, with patients in Canada living 10 years longer than those in the U.S. (Source: CBC | Health)
Source: CBC | Health - March 13, 2017 Category: Consumer Health News Tags: News/Health Source Type: news

Cystic Fibrosis Survival: 10-Year Advantage in Canada vs U.S. (CME/CE)
(MedPage Today) -- Median survival was 50.9 years in Canada, 40.6 years in U.S. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 13, 2017 Category: Primary Care Source Type: news

Cystic Fibrosis Survival Better in Canada Than in U.S.
MONDAY, March 13, 2017 -- People with cystic fibrosis are living longer than ever, but those in Canada live nearly 10 years longer than those in the United States, a new study finds. Cystic fibrosis is a genetic disease that affects the lungs and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 13, 2017 Category: Journals (General) Source Type: news

Phage therapy shown to kill drug-resistant superbug
Phage therapy could offer a safe and effective alternative to antibiotics in the treatment of Cystic Fibrosis lung infections, researchers have demonstrated. Phages are viruses that kill bacteria but are otherwise harmless. A major advantage is that phages only target the harmful bacteria, so there are less side of the effects often associated with antibiotics. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 13, 2017 Category: Science Source Type: news

Phage therapy shown to kill drug-resistant superbug
Scientists from the University of Liverpool have shown that phage therapy could offer a safe and effective alternative to antibiotics in the treatment of Cystic Fibrosis lung infections. Chronic lung infections caused by the bacterium Pseudomonas aeruginosa are becoming increasingly difficult to treat due to antimicrobial resistance (AMR). With limited alternative therapeutic options available this has led to a renewed interest in (bacterio)phage therapy. (Source: World Pharma News)
Source: World Pharma News - March 13, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Study finds differences in lifespan between Canadians and Americans with cystic fibrosis
(Source: St. Michael's Hospital News and Media)
Source: St. Michael's Hospital News and Media - March 13, 2017 Category: Hospital Management Tags: Hospital News Source Type: news

Phage therapy shown to kill drug-resistant superbug
(University of Liverpool) Scientists from the University of Liverpool have shown that phage therapy could offer a safe and effective alternative to antibiotics in the treatment of cystic fibrosis lung infections. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 13, 2017 Category: Infectious Diseases Source Type: news

Vertex to acquire Concert Pharmaceuticals ’ cystic fibrosis drug for $250m
US-based Vertex Pharmaceuticals has signed an agreement to acquire CTP-656, an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator from Concert Pharmaceuticals for up to $250m. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 7, 2017 Category: Pharmaceuticals Source Type: news

Mast Therapeutics subsidiary advances trial for inhaled sodium nitrite solution
Mast Therapeutics (NYSE:MSTX) said today that its subsidiary Aires Pharmaceuticals inked a deal with the University of Pittsburgh related to its phase 1/2 open-label proof-of-concept trial for the company’s AIR001 inhaled sodium nitrite solution in patients with cystic fibrosis. The study will evaluate the nebulized drug as a treatment of Pseudomonas aeruginosa infection in CF patients, according to Mast. The subsidiary plans to provide the drug and nebulizers for the study, but no financial support. Get the full story at our sister site, Drug Delivery Business News. The post Mast Therapeutics subsidiary advance...
Source: Mass Device - March 6, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Wall Street Beat Mast Therapeutics Source Type: news

$160M deal with Concert helps Vertex maintain dominance in cystic fibrosis
Vertex Pharmaceuticals' move on Monday to acquire a once-a-day cystic fibrosis drug for $160 million from a 69-employee Lexington-based biotech could help the Boston company maintain its "dominant" position in the CF pharmaceuticals market, according to one analyst. It could also help the smaller biotech, Concert Pharmaceuticals (Nasdaq: CNCE), head off a possible lawsuit in its future. The deal is part of an effort by Boston-based Vertex (Nasdaq: VRTX) to develop combination-drug regimens that… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 6, 2017 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

PTC says to abandon cystic fibrosis drug after trial failure
(Reuters) - PTC Therapeutics Inc said on Thursday it would stop developing its cystic fibrosis drug after it failed to meet the main goal of a late-stage study. (Source: Reuters: Health)
Source: Reuters: Health - March 2, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Antibiotics used to treat cystic fibrosis increases risk of permanent hearing loss
A powerful class of antibiotics provides life-saving relief for people with cystic fibrosis; however, a new study for the first time reveals the levels at which high cumulative dosages over time significantly increases the risk of permanent hearing loss in these patients. The study suggests physicians who treat patients with cystic fibrosis may be able to consider alternative strategies for treating the symptoms of respiratory infections associated with CF. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 25, 2017 Category: Science Source Type: news

ACOG Recommends Offering All Pregnant Women Additional Carrier Screening (FREE)
By Kelly Young Edited by William E. Chavey, MD, MS All women who are pregnant or are considering becoming pregnant should be offered carrier screening for cystic fibrosis and spinal muscular atrophy and a … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 23, 2017 Category: Primary Care Source Type: news

Paul Ryan Makes The Simplistic Case For Obamacare Repeal: You'll Be Free
House Speaker Paul Ryan (R-Wis.) says that repealing Obamacare is all about freedom. He’s right, although perhaps not in the way he thinks. On Tuesday, Ryan tweeted an argument that he and other conservative leaders have made many times before: “Freedom is the ability to buy what you want to fit what you need. Obamacare is Washington telling you what to buy regardless of your needs.” Freedom is the ability to buy what you want to fit what you need. Obamacare is Washington telling you what to buy regardless of your needs.— Paul Ryan (@PRyan) February 21, 2017 There’s some truth i...
Source: Healthy Living - The Huffington Post - February 22, 2017 Category: Consumer Health News Source Type: news

Student, 18, with cystic fibrosis becomes a cheerleader
Emily Bonney, 18, pictured, from Blackpool, takes up to 60 tablets every day to keep her lungs functioning at a normal rate - but this didn't stop her joining the squad. (Source: the Mail online | Health)
Source: the Mail online | Health - February 15, 2017 Category: Consumer Health News Source Type: news

Overcoming hurdles in CRISPR gene editing to improve treatment
The new gene-editing tool CRISPR/Cas9 holds promise for new treatment of such genetic diseases as cystic fibrosis, muscular dystrophy and hemophilia. But to work well, it must be delivered across the cell membrane and into its nucleus, a process that can trigger cell defenses and'trap'CRISPR/Cas9, reducing its treatment potential. Now, a research team has designed a delivery system using nanoparticles to assist CRISPR/Cas9 across the membrane and avoid entrapment by cellular machinery. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 7, 2017 Category: Science Source Type: news

Overcoming hurdles in CRISPR gene editing to improve treatment
(University of Massachusetts at Amherst) The new gene-editing tool CRISPR/Cas9 holds promise for new treatment of such genetic diseases as cystic fibrosis, muscular dystrophy and hemophilia. But to work well, it must be delivered across the cell membrane and into its nucleus, a process that can trigger cell defenses and 'trap' CRISPR/Cas9, reducing its treatment potential. Now, Vincent Rotello's laboratory at UMass Amherst has designed a delivery system using nanoparticles to assist CRISPR/Cas9 across the membrane and avoid entrapment by cellular machinery. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 7, 2017 Category: Biology Source Type: news

Pulmatrix raises $3m in direct offering
Pulmatrix (NSDQ:PULM) said today that unnamed institutional investors agreed to purchase approximately $3.3 million of shares of common stock in a direct offering. The company said it plans to sell 950,000 shares at $3.50 apiece. Pulmatrix expects the offering, which will close next week, to bring in $3.0 million in proceeds to use for general corporate purposes and paying off some of its debt. The company saw its stock price soar in January after its drug candidate for treating fungal infections in the lungs of cystic fibrosis patients was designated as a ‘qualified infectious disease product’ by the FDA. Foll...
Source: Mass Device - February 3, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Funding Roundup Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news

Updated cystic fibrosis diagnosis guidelines can help in diagnosis, personalized treatment
An international research group of 32 experts from nine countries has updated the guidelines for diagnosing the genetic disease cystic fibrosis. The researchers expect that these guidelines will provide better direction for clinicians looking at patients with symptoms of the disease to make a correct diagnosis and recommend personalized treatment. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 31, 2017 Category: Science Source Type: news

Updated cystic fibrosis diagnosis guidelines can help in diagnosis, personalized treatment
(Johns Hopkins Medicine) An international research group of 32 experts from nine countries has updated the guidelines for diagnosing the genetic disease cystic fibrosis. The researchers expect that these guidelines will provide better direction for clinicians looking at patients with symptoms of the disease to make a correct diagnosis and recommend personalized treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 31, 2017 Category: Global & Universal Source Type: news

Fighting age-related fibrosis to keep organs young
Their research indicates that an already-FDA-approved drug used by cystic fibrosis patients could shield our organs from fibrosis during acute events, like lung infection or heart attack. And looking to the future, they envision that the development of a once-daily pill, capable of inhibiting PAD4, could one day be used as a preventative measure. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 30, 2017 Category: Science Source Type: news

Fighting age-related fibrosis to keep organs young
(Boston Children's Hospital) Their research indicates that an already-FDA-approved drug used by cystic fibrosis patients could shield our organs from fibrosis during acute events, like lung infection or heart attack. And looking to the future, they envision that the development of a once-daily pill, capable of inhibiting PAD4, could one day be used as a preventative measure. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 30, 2017 Category: Global & Universal Source Type: news

‘ They brought me back from death ’: How a woman survived six days without lungs
Melissa Benoit's lungs had been weakened by cystic fibrosis and ravaged by bacterial infections for three years. Then, last February, a bout of swine flu sent her spiraling toward death. By April, she gasped for air with every breath. She had coughing fits so intense her ribs fractured. Her lungs were as hard as a […]Related:Mold-contaminated mouth rinse found at NIH, spokeswoman saysDrug company to help improve Virginia’s prescription drug monitoring systemShe was a model. Then a mysterious digestive disorder starved her to death. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - January 27, 2017 Category: Consumer Health News Source Type: news

Doctors save woman's life by removing her lungs for 6 days
Melissa Benoit, was born with cystic fibrosis, but doctors at Toronto General Hospital discovered she had just hours to live when she was rushed there with a severe infection in April. (Source: the Mail online | Health)
Source: the Mail online | Health - January 26, 2017 Category: Consumer Health News Source Type: news